View Older Stories View More Recent Stories

Dec 13, 2024 07:18AM Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Nov 25, 2024 07:13AM BridgeBio Pharma (BBIO): Attruby approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Nov 22, 2024 07:11PM Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Nov 18, 2024 11:15AM Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Nov 18, 2024 05:30AM BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
Nov 12, 2024 07:30AM BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
Nov 5, 2024 07:30AM BridgeBio Pharma Inc. (BBIO) Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
Nov 5, 2024 07:30AM BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
Oct 24, 2024 07:30AM BridgeBio (BBIO) Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
Oct 24, 2024 07:30AM BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
Oct 3, 2024 07:30AM BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
Sep 30, 2024 07:32AM BridgeBio Pharma (BBIO) Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9
Sep 30, 2024 07:30AM BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Sep 27, 2024 06:00PM BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitaliza
Sep 17, 2024 07:31AM BridgeBio Pharma (BBIO) announces FDA has granted Breakthrough Therapy Designation to oral infigratinib
Sep 17, 2024 07:30AM BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
Sep 10, 2024 04:45PM BridgeBio Pharma (BBIO) Receives FDA’s Regenerative Medicine Advanced Therapy Designation for BBP-812
Sep 10, 2024 04:45PM BridgeBio Pharma (BBIO) Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy
Sep 10, 2024 04:45PM BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
Sep 10, 2024 04:45PM BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
Sep 6, 2024 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aug 30, 2024 10:50AM BridgeBio Pharma (BBIO) Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
Aug 30, 2024 10:50AM BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
Aug 29, 2024 07:30AM BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual
Aug 28, 2024 07:30AM BridgeBio Pharma to Participate in September Investor Events
Aug 26, 2024 07:31AM BridgeBio Pharma Inc. (BBIO) Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with M
Aug 26, 2024 07:30AM BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificia
Aug 19, 2024 07:31AM BridgeBio Pharma Inc. (BBIO) Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
Aug 19, 2024 07:30AM BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
Aug 8, 2024 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2024 07:30AM BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
Jul 23, 2024 07:30AM BridgeBio Pharma Inc. (BBIO) Appoints Thomas Trimarchi as COO
Jul 23, 2024 07:30AM BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
Jul 5, 2024 04:31PM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jun 18, 2024 07:30AM BridgeBio Pharma Inc. (BBIO) Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418
Jun 18, 2024 07:30AM BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9
Jun 10, 2024 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jun 6, 2024 07:30AM BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
Jun 4, 2024 07:32AM BridgeBio Pharma (BBIO) Reports Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia
Jun 4, 2024 07:30AM BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
Jun 3, 2024 04:01PM BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
May 29, 2024 04:01PM Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Tran
May 24, 2024 07:30AM BridgeBio Pharma (BBIO) to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis
May 24, 2024 07:30AM BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
May 15, 2024 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 14, 2024 07:30AM BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
May 13, 2024 07:30AM BridgeBio Pharma Inc. (BBIO) Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy
May 13, 2024 07:30AM BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantl
May 2, 2024 07:30AM BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
May 2, 2024 07:00AM BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
View More Recent Stories View Older Stories